"I know its for cancer drugs, but I don't think its that much of a stretech to ask the same question of a Phase 3 CVD drug.  I'm also wondering if that is something that may have kept (and may still be keeping) Bio-Tech investors away from Resverlogix.  I'm recalling something SanFran posted a coulple years back (or more) about mentioning Resverlogix to others who expressed a similar sentiment, something along the lines of, "if Apabetalone had any real potential a BP player would have climbed on board or bought them out"."

Tell that to Esperion (bempedoic acid),  Amarin (Vascepa) or The Medicines Company (Inclisiran).

BDAZ